Despite the economic headwinds, Pfizer Inc. (PFE) reported impressive financials for the third quarter of 2022 and updated its full-year financial outlook. It raised the lower end of full-year 2022 revenue guidance to a range of $99.5 to $102 billion.
It increased 2022 revenue guidance for Comirnaty by $2 billion to approximately $34 billion and reaffirmed revenue guidance for Paxlovid of nearly $22 billion. In addition, PFE expects an adjusted EPS of $6.40 to $6.50, up from the prior guidance of $6.30 to $6.45.
